+369.5%
ALAB vs MRNA
+39.2%
+330.3%
-63.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.4% | +5.4% | -3.0% | +2.1% |
| 7D | -6.2% | -1.1% | -5.1% | -6.1% |
| 30D | -8.7% | +126.1% | -134.8% | -15.1% |
| 3M | -20.7% | +190.0% | -210.8% | -31.4% |
| 6M | +133.5% | +157.2% | -23.7% | +106.7% |
| YTD | +75.1% | +388.2% | -313.1% | +30.9% |
| 1Y | +25.0% | +467.0% | -442.0% | -10.7% |
| All | +369.5% | +39.2% | +330.3% | +313.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling